Fludarabine and rituximab with escalating doses of lenalidomide followed by lenalidomide/rituximab maintenance in previously untreated chronic lymphocytic leukaemia (CLL): the REVLIRIT CLL-5 AGMT phase I/II study

Despite recent advances, chemoimmunotherapy remains a standard for fit previously untreated chronic lymphocytic leukaemia patients. Lenalidomide had activity in early monotherapy trials, but tumour lysis and flare proved major obstacles in its development. We combined lenalidomide in increasing dose...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Ann Hematol
Hauptverfasser: Egle, Alexander, Steurer, Michael, Melchardt, Thomas, Weiss, Lukas, Gassner, Franz Josef, Zaborsky, Nadja, Geisberger, Roland, Catakovic, Kemal, Hartmann, Tanja Nicole, Pleyer, Lisa, Voskova, Daniela, Thaler, Josef, Lang, Alois, Girschikofsky, Michael, Petzer, Andreas, Greil, Richard
Format: Artigo
Sprache:Inglês
Veröffentlicht: Springer Berlin Heidelberg 2018
Schlagworte:
Original Article
Online Zugang:https://ncbi.nlm.nih.gov/pmc/articles/PMC6097797/
https://ncbi.nlm.nih.gov/pubmed/29862437
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1007/s00277-018-3380-z
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!

Ähnliche Einträge